Treatment of experimental renal osteodystrophy with pamidronate

Kidney International

Volumn 74, Issue 3, 2008, Pages 319-327

  Jokihaara, Jarkko ^a,b   Pörsti, Ilkka H ^b,c   Kööbi, Peeter ^b,c   Jolma, Pasi M ^b,c   Mustonen, Jukka T ^b,c   Saha, Heikki H T ^c   Sievänen, Harri ^d   Kannus, Pekka ^b,d   Iwaniec, Urszula T ^e   Turner, Russell T ^e   Järvinen, Teppo L N ^b,c,f  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TAMPERE   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d UKK INSTITUTE FOR HEALTH PROMOTION RESEARCH   (Finland)

^e OREGON STATE UNIVERSITY   (United States)

^f TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Biomechanics; Bisphosphonates; Bone; Chronic renal insufficiency; Histomorphometry

Indexed keywords

CALCITRIOL; CREATININE; PAMIDRONIC ACID; PARATHYROID HORMONE; PHOSPHATE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE MINERAL; BONE STRUCTURE; BONE TURNOVER; CELL SURFACE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MECHANISM; FEMUR SHAFT; FIBROBLAST; HORMONE BLOOD LEVEL; MALE; METAPHYSIS; MORPHOMETRICS; NEPHRECTOMY; NONHUMAN; OSTEOID; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RAT; RENAL OSTEODYSTROPHY; UNINEPHRECTOMY; UREA BLOOD LEVEL;

EID: 47349083391     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.180     Document Type: Article

References (68)

1. Parfitt AM. A structural approach to renal bone disease. J Bone Miner Res 1998; 13: 1213-1220.
2. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953.
3. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80-100.
4. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996; 97: 2692-2696.
5. Geng Z, Monier-Faugere MC, Bauss F et al. Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure. Clin Nephrol 2000; 54: 45-53.
6. Jamal SA, Bauer DC, Ensrud KE et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 2007; 22: 503-508.
7. Miller PD, Roux C, Boonen S et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005; 20: 2105-2115.
8. Torregrosa JV, Moreno A, Mas M et al. Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. Kidney Int Suppl 2003; 85: S88-S90.
9. Wetmore JB, Benet LZ, Kleinstuck D et al. Effects of short-term alendronate on bone mineral density in haemodialysis patients. Nephrology (Carlton) 2005; 10: 393-399.
10. Massry SG, Coburn JW, Chertow GM et al. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201.
11. Persy V, De Broe M, Ketteler M. Bisphosphonates prevent experimental vascular calcification: treat the bone to cure the vessels? Kidney Int 2006; 70: 1537-1538.
12. London GM, Marty C, Marchais SJ et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951.
13. Fan SL, Cunningham J. Bisphosphonates in renal osteodystrophy. Curr Opin Nephrol Hypertens 2001; 10: 581-588.
14. Mashiba T, Hirano T, Turner CH et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000; 15: 613-620.
15. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36: 1115-1121.
16. van der Meulen MC, Jepsen KJ, Mikic B. Understanding bone strength: size isn't everything. Bone 2001; 29: 101-104.
17. Frost HM. On our age-related bone loss: insights from a new paradigm. J Bone Miner Res 1997; 12: 1539-1546.
18. Burr DB. Muscle strength, bone mass, and age-related bone loss. J Bone Miner Res 1997; 12: 1547-1551.
19. Järvinen TL, Sievänen H, Jokihaara J et al. Revival of bone strength: the bottom line. J Bone Miner Res 2005; 20: 717-720.
20. Jokihaara J, Järvinen TL, Jolma P et al. Renal insufficiency-induced bone loss is associated with an increase in bone size and preservation of strength in rat proximal femur. Bone 2006; 39: 353-360.
21. Jokihaara J, Pörsti I, Pajamäki I et al. Paricalcitol (19-nor-1,25-(OH)2D2) in the treatment of experimental renal bone disease. J Bone Miner Res 2006; 21: 745-751.
22. Nitta K, Akiba T, Suzuki K et al. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 2004; 44: 680-688.
23. Coco M, Glicklich D, Faugere MC et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003; 14: 2669-2676.
24. Fan SL, Almond MK, Ball E et al. Pamidronate therapy as prevention of bone loss following renal transplantation1. Kidney Int 2000; 57: 684-690.
25. Haas M, Leko-Mohr Z, Roschger P et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 2003; 63: 1130-1136.
26. Grotz W, Nagel C, Poeschel D et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 2001; 12: 1530-1537.
27. Fan SL, Kumar S, Cunningham J. Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation. Kidney Int 2003; 63: 2275-2279.
28. Rossini M, Gatti D, Isaia G et al. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 2001; 16: 113-119.
29. Rauch F, Travers R, Plotkin H et al. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002; 110: 1293-1299.
30. Rauch F, Plotkin H, Zeitlin L et al. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 2003; 18: 610-614.
31. Weber M, Roschger P, Fratzl-Zelman N et al. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta. Bone 2006; 39: 616-622.
32. Cranney A, Guyatt G, Griffith L et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 570-578.
33. Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol 2005; 17: 462-466.
34. Speiser PW, Clarson CL, Eugster EA et al. Bisphosphonate treatment of pediatric bone disease. Pediatr Endocrinol Rev 2005; 3: 87-96.
35. Price PA, Roublick AM, Williamson MK. Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int 2006; 70: 1577-1583.
36. Langman CB, Salusky IB, Greenbaum L et al. K/DOQI clinical practice guideline for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 2005; 46: S12-S100.
37. Borah B, Dufresne TE, Ritman EL et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 2006; 39: 345-352.
38. Miller SC, Jee WS. The effect of dichloromethylene diphosphonate, a pyrophosphate analog, on bone and bone cell structure in the growing rat. Anat Rec 1979; 193: 439-462.
39. Sato M, Grasser W, Endo N et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88: 2095-2105.
40. Iwaniec UT, Mosekilde L, Mitova-Caneva NG et al. Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats. Endocrinology 2002; 143: 2515-2526.
41. Lotinun S, Evans GL, Bronk JT et al. Continuous parathyroid hormone induces cortical porosity in the rat: effects on bone turnover and mechanical properties. J Bone Miner Res 2004; 19: 1165-1171.
42. Frost HM. Bone's mechanostat: a 2003 update. Anat Rec 2003; 275A: 1081-1101.
43. Turner CH, Burr DB. Basic biomechanical measurements of bone: a tutorial. Bone 1993; 14: 595-608.
44. Felsenfeld AJ, Jara A, Avedian G et al. Effects of fasting, feeding, and bisphosphonate administration on serum calcitriol levels in phosphate-deprived rats. Kidney Int 2000; 58: 1016-1022.
45. Yamamoto T, Imanishi Y, Kinoshita E et al. The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome. J Bone Miner Metab 2005; 23: 231-237.
46. Miller MA, Chin J, Miller SC et al. Disparate effects of mild, moderate, and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiency. Bone 1998; 23: 257-266.
47. Jablonski G, Klem KH, Attramadal A et al. Surgically induced uremia in rats. I: effect on bone strength and metabolism. Biosci Rep 1993; 13: 275-287.
48. Sanchez CP, He YZ, Leiferman E et al. Bone elongation in rats with renal failure and mild or advanced secondary hyperparathyroidism. Kidney Int 2004; 65: 1740-1748.
49. Jolma P, Kööbi P, Kalliovalkama J et al. Treatment of secondary hyperparathyroidism by high calcium diet is associated with enhanced resistance artery relaxation in experimental renal failure. Nephrol Dial Transplant 2003; 18: 2560-2569.
50. Pörsti I, Fan M, Kööbi P et al. High calcium diet downregulates kidney angiotensin-converting enzyme in experimental renal failure. Kidney Int 2004; 66: 2155-2166.
51. Bukowski JF, Dascher CC, Das H. Alternative bisphosphonate targets and mechanisms of action. Biochem Biophys Res Commun 2005; 328: 746-750.
52. Frith JC, Rogers MJ. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. J Bone Miner Res 2003; 18: 204-212.
53. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004; 114: 623-633.
54. Ylitalo R, Oksala O, Yla-Herttuala S et al. Effects of clodronate (dichloromethylene bisphosphonate) on the development of experimental atherosclerosis in rabbits. J Lab Clin Med 1994; 123: 769-776.
55. Bourrin S, Ammann P, Bonjour JP et al. Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bisphosphonate or selective estrogen receptor modulator therapy in aged rats. Bone 2002; 30: 195-200.
56. Mekraldi S, Toromanoff A, Rizzoli R et al. Pamidronate prevents bone loss and decreased bone strength in adult female and male rats fed an isocaloric low-protein diet. J Bone Miner Res 2005; 20: 1365-1371.
57. Mayahara M, Sasaki T. Cellular mechanism of inhibition of osteoclastic resorption of bone and calcified cartilage by long-term pamidronate administration in ovariectomized mature rats. Anat Rec A Discov Mol Cell Evol Biol 2003; 274: 817-826.
58. Pelker RR, Friedlaender GE, Markham TC et al. Effects of freezing and freeze-drying on the biomechanical properties of rat bone. J Orthop Res 1984; 1: 405-411.
59. Sedlin ED, Hirsch C. Factors affecting the determination of the physical properties of femoral cortical bone. Acta Orthop Scand 1966; 37: 29-48.
60. Turner RT, Evans GL, Cavolina JM et al. Programmed administration of parathyroid hormone increases bone formation and reduces bone loss in hindlimb-unloaded ovariectomized rats. Endocrinology 1998; 139: 4086-4091.
61. Järvinen TL, Kannus P, Sievänen H et al. Randomized controlled study of effects of sudden impact loading on rat femur. J Bone Miner Res 1998; 13: 1475-1482.
62. Järvinen TL, Sievänen H, Kannus P et al. Dual-energy X-ray absorptiometry in predicting mechanical characteristics of rat femur. Bone 1998; 22: 551-558.
63. Sievänen H, Kannus P, Järvinen M. Precision of measurement by dual-energy X-ray absorptiometry of bone mineral density and content in rat hindlimb in vitro. J Bone Miner Res 1994; 9: 473-478.
64. Gluer CC, Blake G, Lu Y et al. Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques. Osteoporos Int 1995; 5: 262-270.
65. Pajamäki I, Kannus P, Vuohelainen T et al. The bone gain induced by exercise in puberty is not preserved through a virtually life-long deconditioning: a randomized controlled experimental study in male rats. J Bone Miner Res 2003; 18: 544-552.
66. Leppanen O, Sievanen H, Jokihaara J et al. Three-point bending of rat femur in the mediolateral direction: introduction and validation of a novel biomechanical testing protocol. J Bone Miner Res 2006; 21: 1231-1237.
67. Järvinen TL, Kannus P, Pajamäki I et al. Estrogen deposits extra mineral into bones of female rats in puberty, but simultaneously seems to suppress the responsiveness of female skeleton to mechanical loading. Bone 2003; 32: 642-651.
68. Järvinen TL, Pajamäki I, Sievänen H et al. Femoral neck response to exercise and subsequent deconditioning in young and adult rats. J Bone Miner Res 2003; 18: 1292-1299.